A study to evaluate the efficacy of sublingual cannabinoid based medicineextract compared with placebo for the treatment of Insomnia.
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
Price : $35 *
At a glance
- Drugs ZTL-101 (Primary)
- Indications Insomnia
- Focus Adverse reactions
- 19 Jan 2018 Status changed from planning to not yet recruiting.
- 18 Jan 2018 New trial record
- 28 Nov 2017 Accordind to a Zelda Therapeutics media release, trial may start in the first quarter of 2018. Preliminary results from this trial is anticipated in third quarter of 2018.